A federal court ruled this week that IonPath's MIBIscope does not infringe on Fluidigm's technology, though the company has indicated it will likely appeal.
Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.
A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.